Corrigendum to “The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2021;100:225–237
Titel:
Corrigendum to “The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2021;100:225–237
Auteur:
Ariceta, Gema Dixon, Bradley P. Kim, Seong Heon Kapur, Gaurav Mauch, Teri Ortiz, Stephan Vallee, Marc Denker, Andrew E. Kang, Hee Gyung Greenbaum, Larry A.